OOIR: Observatory of International Research

Papers

(The H4-Index of Drug Discovery Today is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
Contents page 2	213
Contents page	201
Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors	186
Mitochondrial dysfunction: A potential target for Alzheimer’s disease intervention and treatment	179
New views on endothelial dysfunction in gestational hypertension and potential therapy targets	145
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	136
Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective	132
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	123
Tubulin targeting agents and their implications in non-cancer disease management	116
Gastroretentive drug delivery systems: A holy grail in oral delivery	112
General aspects of powder rheology applied to pharmaceutical formulations	106
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	106
Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity	103
The potential value of 5-androstenediol in countering acute radiation syndrome	100
Recent development in the design of small ‘drug-like’ and nanoscale glycomimetics against Escherichia coli infections	100
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	98
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	95
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	88
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	87
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	85
Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases	83
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	80
Antibody–drug conjugates: What drives their progress?	79
Specificity of pharmacokinetic modeling of nanomedicines	77
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	77

The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	77
Computational modeling approaches and regulatory pathways for drug combinations	75
Graph neural networks for automated de novo drug design	73
Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants	72
CIPDB: A biological structure databank for studying cation and π interactions	71
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	70
The recent progress of deep-learning-based in silico prediction of drug combination	70
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	69
Models and approaches to comprehend and address glial inflammation following spinal cord injury	69
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	68
Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics	68
Contents page 2	68
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	67
Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases	66
Advancing pharmacogenetics research in Africa: the “Project Africa GRADIENT” initiative	66
Targeted protein degradation: current molecular targets, localization, and strategies	65
Organoids in modelling infectious diseases	63
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	62
Benchmarking the mechanisms of frequent hitters: limitation of PAINS alerts	62
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein	61
Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities	60
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases	60
Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection	58
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases	56
Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis	56
Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer	56
Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options	55
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States	54
A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs	54